Ocular Therapeutix (NASDAQ: OCUL) and Lombard Medical (OTCMKTS:EVARF) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk.
Risk and Volatility
Ocular Therapeutix has a beta of 1.53, suggesting that its share price is 53% more volatile than the S&P 500. Comparatively, Lombard Medical has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500.
Earnings and Valuation
This table compares Ocular Therapeutix and Lombard Medical’s revenue, earnings per share and valuation.
||Earnings Per Share
Lombard Medical has higher revenue and earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Lombard Medical, indicating that it is currently the more affordable of the two stocks.
This table compares Ocular Therapeutix and Lombard Medical’s net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Institutional and Insider Ownership
43.3% of Ocular Therapeutix shares are held by institutional investors. Comparatively, 39.9% of Lombard Medical shares are held by institutional investors. 26.1% of Ocular Therapeutix shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
This is a breakdown of current ratings and target prices for Ocular Therapeutix and Lombard Medical, as provided by MarketBeat.com.
||Strong Buy Ratings
Ocular Therapeutix presently has a consensus target price of $20.67, indicating a potential upside of 313.33%. Given Ocular Therapeutix’s higher possible upside, analysts plainly believe Ocular Therapeutix is more favorable than Lombard Medical.
Lombard Medical beats Ocular Therapeutix on 7 of the 13 factors compared between the two stocks.
About Ocular Therapeutix
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP (travoprost insert) is in Phase III clinical development for glaucoma and ocular hypertension. Its earlier stage assets include OTX-TIC, a sustained release travoprost intracameral injection for the treatment of moderate to severe glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. These injections include the development of OTX-TKI, a tyrosine kinase inhibitor, and, in collaboration with Regeneron an extended release protein-based anti-vascular endothelial growth factor trap.
About Lombard Medical
Lombard Medical, Inc. is a medical technology company. The Company specializes in developing, manufacturing, and marketing endovascular stent-grafts that address medical needs in the repair of aortic aneurysms. The Company’s Aorfix is an abdominal aortic aneurysm (AAA) stent-graft for the treatment of AAAs with angulation at the neck of the aneurysm of over 90 degrees. The Company supplies Aorfix pre-loaded into a delivery system, Aorflex, which is designed for accurate placement of Aorfix in the abdominal aorta. Once Aorfix is properly placed within the abdominal aorta, it provides a conduit for blood flow, thereby relieving pressure within the weakened or aneurysmal section of the vessel wall, which reduces the potential for the AAA to rupture. It also offers IntelliFlex, which is a delivery system technology created for Aorfix AAA stent graft, and Altura Endovascular Stent Graft System that offers a simple and predictable solution to the treatment of standard AAA anatomies.
Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.